A long-term study evaluated tofersen for SOD1-ALS, a rare genetic form of amyotrophic lateral sclerosis that accounts for roughly 2% of ALS cases. Average life expectancy for people with SOD1-ALS is two to three years from symptom onset. Tofersen is an antisense oligonucleotide that lowers production of the mutated SOD1 protein. The drug received FDA approval in 2023 under an accelerated pathway.
The phase 3 trial lasted six months and continued as an open-label extension co-led by Washington University School of Medicine in St. Louis. Of 108 original participants, 46 completed follow-up after 3.5 to 5.5 years. Long-term use delayed symptom progression and death, and about one-quarter of participants showed stabilization or improvement over roughly three years, including better grip strength and respiratory function.
Common side effects included headache, procedural pain, falls and back or limb pain. Nine participants (9%) had more serious inflammatory neurological side effects, which were treated successfully. A multisite trial now tests whether tofersen can prevent or delay disease in people with the gene variant but no symptoms. Biogen funded the study and provided the drug, and investigators disclosed ties to the company.
Difficult words
- antisense oligonucleotide — a short lab-made molecule that blocks a gene
- mutate — to change in genetic material or formmutated
- open-label extension — a study phase where participants know the treatment
- stabilization — a state of little or no further change
- inflammatory — relating to swelling or immune-system reaction
- follow-up — a later check to see health or progress
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you take a drug that can slow a serious disease but has some risk of inflammatory side effects? Why or why not?
- The study continued as an open-label extension with long follow-up. How important is long-term follow-up for you when judging a new treatment, and why?
- The article says a new trial will test use in people with the gene variant but no symptoms. What are the advantages and concerns of treating people before symptoms start?
Related articles
PAHO issues first guide for tungiasis treatment
PAHO has published the first evidence-based guide to treat tungiasis, recommending low-viscosity dimethicone and warning against unsafe manual removal. The disease affects millions in Latin America, the Caribbean and Sub-Saharan Africa.
Cherry compounds may slow triple-negative breast cancer
Researchers at Texas A&M report that anthocyanins from dark sweet cherries slowed tumour growth and reduced metastasis in mice, and that combining them with chemotherapy helped control tumours. Further research is needed on safety and absorption.
Mpox may be spreading quietly in Nigeria
A study in Nigeria tested archived blood from healthy adults and found signs of hidden mpox exposure. Some people had old smallpox antibodies and a small number showed recent immune responses without symptoms, suggesting low-level virus circulation.
Africa uses AI to strengthen health systems and self-reliance
At the CPHIA conference in Durban, Africa CDC said AI and digital tools can help protect 1.4 billion people, improve surveillance and support primary health care. Data governance, infrastructure and domestic financing are key concerns.